This compound is a key chiral intermediate in the synthesis of triazole-based antifungal medications, such as those in the azole class (e.g., related to itraconazole or ketoconazole derivatives). The final drugs produced using this intermediate inhibit lanosterol 14α-demethylase, disrupting ergosterol biosynthesis essential for fungal cell membranes. This leads to increased permeability, leakage, and death of fungal cells, making them effective against pathogens like Candida species and Aspergillus. The specific (2R,3R) stereoisomer ensures proper configuration for downstream reactions. Its methanesulfonate salt form provides enhanced solubility and stability for use in pharmaceutical manufacturing processes. Research also explores its role in developing antifungal coatings for medical devices to prevent biofilm formation and colonization.